Eli Lilly And Co LLY is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe.What Happened: A recent report says Eli Lilly is seeking medical records of people who took knockoff weight loss drugs.The request, reported by Bloomberg, is being done for safety reasons according to the pharmaceutical company.Eli Lilly is building a case against businesses that are selling knockoffs of the ...

文章核心观点 - 辉瑞公司的阿尔茨海默病药物Kisunla(donanemab)获得日本批准上市,用于治疗轻度认知障碍和轻度痴呆期的早期症状性阿尔茨海默病患者 [1] - Kisunla是第二个获批的针对阿尔茨海默病特定病因(淀粉样蛋白斑块)的药物,第一个是碧恩-爱斯艾公司的Leqembi [2] - 辉瑞公司认为日本是Kisunla的重要市场,因为日本预计到2030年痴呆患者将超过500万,其中阿尔茨海默病占67%以上 [4] 根据目录分别总结 Kisunla的优势 - Kisunla是唯一一种可在淀粉样蛋白斑块清除后停药的针对性疗法,可降低治疗成本和患者负担 [5] - Kisunla需要每4周静脉输注一次,相比碧恩-爱斯艾的Leqembi每2周输注一次更为方便 [6] 行业竞争格局 - 阿尔茨海默病领域竞争激烈,卡萨瓦科学和普罗蒂纳等公司也在开发针对该适应症的抗体候选药物 [7] - 卡萨瓦科学的口服药物simufilam正在进行III期临床试验,预计2024年底和2025年中期公布结果 [7] - 普罗蒂纳正在评估多个早期阶段的阿尔茨海默病候选药物,包括针对淀粉样蛋白的PRX012和针对淀粉样蛋白和tau蛋白的PRX123疫苗 [7] 辉瑞公司评级 - 辉瑞公司目前被Zacks评级为强烈买入(Zacks Rank 1) [8]

The opportunities for artificial intelligence (AI) to have an impact in the healthcare space are enormous.Over the last couple of years, artificial intelligence (AI) has emerged as the world's next megatrend. Thus far, breakthroughs in generative AI have mostly revolved around the technology industry.In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most powerful graphics processing units (GPUs) has been off the charts, and investors hav ...

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year studyThe safety profile at three years was consistent with the previously published two-year resultsINDIANAPOLIS, Sept. 25, 2024 /PRNewswire/ -- More than 80 percent of adults and adolescents with moderate-to-severe ...

Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as peopl ...

Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.Nov. 30, 2022, will go down as a defining moment in modern history. That's the day OpenAI released ChatGPT to the masses. Just like that, euphoria about artificial intelligence (AI) took over the world.One of the biggest beneficiaries of the AI boom has been semiconductor specialist Nvidia. If you had bought shares of Nvidia on the same day that ChatGPT was intr ...

文章核心观点 - 该文章是一名全职分析师撰写的,旨在为其投资组合提供独特的见解和知识 [1] - 分析师表示自己没有持有任何相关公司的股票、期权或类似衍生工具,也没有在未来72小时内进行任何此类交易的计划 [1] - 文章仅提供信息性分析,不构成专业投资建议,投资者在进行任何投资前应进行深入研究并尽职调查,因为交易存在许多风险,包括资本损失 [2] - Seeking Alpha 声明过去的业绩不能保证未来的结果,不会就任何投资是否适合特定投资者提供任何建议或意见,分析师观点可能不代表 Seeking Alpha 的整体立场 [2] 行业相关内容 无 公司相关内容 无

文章核心观点 - 制药公司Eli Lilly是全球最大的制药公司,市值超过8000亿美元,主要得益于其糖尿病新药Mounjaro和Zepbound的快速增长 [1] - 过去12个月Eli Lilly的股价上涨了58%,几乎是标普500指数和纳斯达克综合指数涨幅的两倍 [1] - 分析师认为Eli Lilly可能会在年底前再次提高股息,而不是进行股票拆分 [1] 公司概况 - Eli Lilly自1972年以来一直在稳步提高每股股息,从最初的每季度0.01美元增加到现在的1.30美元(每年5.20美元) [2] - 2015年开始Eli Lilly开始持续提高股息,这可能与其糖尿病新药Trulicity获批上市有关 [2] - 除了糖尿病新药,Eli Lilly的癌症药物Verzenio适应症扩大以及阿尔茨海默治疗药物获批也预示着公司未来还有进一步增长空间 [3] 股息政策 - Eli Lilly每年12月都会宣布提高股息,次年2月中旬除息 [4] - 分析师认为Eli Lilly很可能会在今年12月再次提高股息,这为投资者带来了被动收益的机会 [5]

公司概况 - 公司是一家专注于发掘高增长潜力和价值被低估的投资机会的研究公司 [1] - 公司的研究分析师擅长解读各种新闻、事件、财报等,发现潜在的投资机会和风险 [1] - 公司的研究分析师被TipRanks和Seeking Alpha评为行业顶级分析师 [1] 投资策略 - 公司采取机会主义的投资策略,专注于识别风险收益比较优的增长型投资机会 [1] - 公司倾向于避开过度炒作和估值过高的股票,而是关注那些遭受重创但仍有显著上涨潜力的股票 [1] - 公司的投资组合专注于那些拥有强劲基本面、买入动力和扭亏为盈机会的增长型股票 [2] - 公司的投资组合聚焦于18-24个月内有望实现投资价值的机会 [2]

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.Berkshire Hathaway recently crossed the $1 trillion market cap, becoming the first non-tech stock to do so. While the stock has given back some gains in recent days and fallen below that threshold, it's still an incredible accomplishment nonetheless.But there's another non-tech stock which could be worth $1 trillion in the near future, and that's Eli Lilly (LLY -0.13%). The healthcare giant ...